COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.
Sponsor: Peking Union Medical College Hospital
You may qualify if…
- ✓ 1. Patients who agree to participate in the trial and sign the informed consents.
- ✓ 2. Male or female, ≥18 years old.
- ✓ 3. Diagnosed of lung carcinoma by histological and cytological examinations.
- ✓ 4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.
- ✓ 5. Recorded history of COVID19 infection.
- ✓ 6. Sufficiently functional organs.
- ✓ 7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.
You may not qualify if…
- ✕ 1. Life expectance less than 3 months.
- ✕ 2. Less than 3 months since last confirmed COVID-19 infection.
- ✕ 3. Patients unable to return the hospital for follow-up.
- ✕ 4. Patients allergic to COVID-19 vaccine.
- ✕ 5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.
Source: ClinicalTrials.gov · NCT06168032 · last updated 2023-12-13